Full side-by-side comparison — 2026
Data as of May 20, 2026 · Updated automatically
| Metric | ABBV | JNJ |
|---|---|---|
| Current Price | 215.40 | 230.48 |
| Previous Close | 212.30 | 229.32 |
| Metric | ABBV | JNJ |
|---|---|---|
| Trailing P/E | 103.16 | 26.24 |
| Forward P/E | 12.90 | 17.84 |
| Price / Book | -55.59 | 6.72 |
| Price / Sales | 5.89 | 5.66 |
| EV / EBITDA | 14.49 | 16.86 |
| Metric | ABBV | JNJ |
|---|---|---|
| Dividend Yield | 0.0320% | 0.0229% |
| Dividend Rate (Annual) | 6.74 | 5.20 |
| 5-Year Avg Yield | 3.96% | 2.77% |
| Payout Ratio | 3.2476% | 0.5952% |
| Metric | ABBV | JNJ |
|---|---|---|
| Beta (Volatility) | 0.31 | 0.26 |
| Debt / Equity | 4789.60 | 67.73 |
| Quick Ratio | 0.52 | 0.69 |
| Current Ratio | 0.80 | 1.03 |
| Metric | ABBV | JNJ |
|---|---|---|
| Revenue Growth | 0.1240% | 0.0990% |
| Earnings Growth | -0.4620% | -0.5290% |
| Return on Equity | 62.2500% | 0.2642% |
| Revenue / Share | 35.50 | 40.02 |
| Trailing EPS | 2.03 | 8.64 |
| Forward EPS | 16.23 | 12.71 |
| Metric | ABBV | JNJ |
|---|---|---|
| Analyst Mean Target | 252.90 | 252.96 |
| Analyst High Target | 328.00 | 285.00 |
| Analyst Low Target | 184.00 | 155.00 |
AbbVie Inc. (ABBV) leads on 10 of 19 comparable metrics.
AbbVie Inc. is the stronger pick for income investors, while Johnson & Johnson may appeal to conservative investors.
This comparison is based on publicly available financial data and is for informational purposes only. It is not investment advice. Past performance does not guarantee future results.
ABBV trades at 103.2x earnings vs JNJ at 26.2x — a gap this large often reflects different growth expectations, not simple mispricing.
ABBV carries 4790x debt-to-equity — significantly higher than JNJ's 68x. High leverage amplifies both gains and losses.
ABBV's earnings declined 46% — declining profits may mean current valuation metrics (PE, payout ratio) are misleading.
Based on analyst mean price targets. Estimates are not guaranteed and may not reflect future performance.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare …
View ABBV details →Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in …
View JNJ details →Add both to AllInvestView and compare their real-time performance, dividends, and gain/loss side by side.
Start Free Portfolio